Rutaecarpine (Synonyms: Rutecarpine)

Name: Rutaecarpine
Brand: MedChemExpress
SKU: HY-N0147
Rating: 5.0 (6 reviews)

Cat. No.: HY-N0147 Purity: 99.09%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of COX-2 with an IC₅₀ value of 0.28 μM. Rutaecarpine can target and activate the NRF2/HO-1 pathway to reduce craniofacial injury. Rutaecarpine sttenuates oxidative stress-induced traumatic brain injury (TBI) and reduces secondary injury via the PGK1/KEAP1/NRF2 signaling pathway. Rutaecarpine can cross the blood-brain barrier (BBB).

For research use only. We do not sell to patients.

CAS No. : 84-26-4

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Rutaecarpine:

Rutaecarpine (Standard) Get quote

6 Publications Citing Use of MCE Rutaecarpine

Cell Proliferation/Viability Assay

ELISA

: Rutaecarpine purchased from MedChemExpress. Usage Cited in: BMC Complement Med Ther. 2023 Dec 1;23(1):433. [Abstract]; The proliferative ability of HT29 and LS180 cells that disposed in different concentrations of Isorhamnetin, Evodiamine, Quercetin and Rutaecarpine (0.5 µM, 1 µM, 2 µM, 4 µM, 8 µM and 16 µM).

: Rutaecarpine purchased from MedChemExpress. Usage Cited in: BMC Complement Med Ther. 2023 Dec 1;23(1):433. [Abstract]; The supernatant concentration of TNF-α after HT29 and LS180 cells pretreating with Rutaecarpine (0.5 µM, 1 µM, 2 µM and 4 µM) by ELISA.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

COX-2

0.28 μM (IC₅₀, in BMMC)

COX-1

8.7 μM (IC₅₀, in BMMC)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	14.5 μM Compound: 11a	Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC	10.1016/0960-894X(95)00046-V
A549	GI₅₀	14.5 μM Compound: 49	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 36375335]
A549	IC₅₀	> 20 μM Compound: Fig 1A, Cpd 1	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 38897138]
CCD-18Co	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
CCD-841CoN	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
CCRF-CEM	GI₅₀	18.9 μM Compound: 11a	Tested for in vitro cytotoxicity against leukemia cell line CCRF-CEM Tested for in vitro cytotoxicity against leukemia cell line CCRF-CEM	10.1016/0960-894X(95)00046-V
DU-145	GI₅₀	31.65 μM Compound: 49	Growth inhibition of human DU-145 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human DU-145 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 36375335]
HCT-116	GI₅₀	33.89 μM Compound: 49	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition Anticancer activity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 36375335]
HCT-116	IC₅₀	31.1 μM Compound: 1	Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
HCT-15	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
HEK293	EC₅₀	2.06 μM Compound: 2	Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of channel current at -60 mV holding potential by whole-cell patch-clamp method Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of channel current at -60 mV holding potential by whole-cell patch-clamp method	[PMID: 27159637]
HL-60	GI₅₀	19.8 μM Compound: 49	Growth inhibition of human HL-60 cells incubated for 4 days by WST assay Growth inhibition of human HL-60 cells incubated for 4 days by WST assay	[PMID: 36375335]
HT-29	GI₅₀	31.6 μM Compound: 49	Growth inhibition of human HT-29 cells by SRB assay Growth inhibition of human HT-29 cells by SRB assay	[PMID: 36375335]
HT-29	IC₅₀	118 μM Compound: 49	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay	[PMID: 36375335]
HUVEC	IC₅₀	16.54 μM Compound: 49	Cytotoxicity against HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36375335]
HeLa	EC₅₀	26.1 μM Compound: 1a	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 28958621]
HeLa	IC₅₀	26 μM Compound: Fig 1A, Cpd 1	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 38897138]
Hs-578T	GI₅₀	22.6 μM Compound: 11a	Tested for in vitro cytotoxicity against breast cancer cell line Hs 578.T Tested for in vitro cytotoxicity against breast cancer cell line Hs 578.T	10.1016/0960-894X(95)00046-V
Hs-578T	GI₅₀	22.6 μM Compound: 49	Growth inhibition against human Hs-578T cells incubated for 48 hrs by sulforhodamine B reagent assay Growth inhibition against human Hs-578T cells incubated for 48 hrs by sulforhodamine B reagent assay	[PMID: 36375335]
K562	GI₅₀	25.77 μM Compound: 49	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 36375335]
LS174T	IC₅₀	6.1 μM Compound: 1	Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
MCF-10A	IC₅₀	> 20 μM Compound: Fig 1A, Cpd 1	Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 38897138]
MCF7	GI₅₀	19.57 μM Compound: 49	Growth inhibition of human MCF7 cells incubated for 48 hrs by SRB assay Growth inhibition of human MCF7 cells incubated for 48 hrs by SRB assay	[PMID: 36375335]
MCF7	IC₅₀	74.5 μM Compound: 49	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 36375335]
MCF7	IC₅₀	> 20 μM Compound: Fig 1A, Cpd 1	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 38897138]
MDA-MB-231	IC₅₀	117.6 μM Compound: 49	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 36375335]
NCI-N87	GI₅₀	8.41 μM Compound: 49	Growth inhibition of human NCI-N87 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Growth inhibition of human NCI-N87 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 36375335]
OVCAR-4	GI₅₀	18.9 μM Compound: 11a	Tested for in vitro cytotoxicity against ovarian cancer cell line OVCAR-4 Tested for in vitro cytotoxicity against ovarian cancer cell line OVCAR-4	10.1016/0960-894X(95)00046-V
OVCAR-4	GI₅₀	18.9 μM Compound: 49	Growth inhibition of human OVCAR-4 cells by SRB assay Growth inhibition of human OVCAR-4 cells by SRB assay	[PMID: 36375335]
P388	IC₅₀	36.8 μM Compound: 49	Cytotoxicity against mouse P388 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against mouse P388 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 36375335]
RKO	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
SF-295	GI₅₀	14.1 μM Compound: 49	Growth inhibition against human SF-295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition against human SF-295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 36375335]
SMMC-7721	IC₅₀	18.9 μM Compound: 49	Anticancer activity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by CCK8 assay Anticancer activity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by CCK8 assay	[PMID: 36375335]
SW480	IC₅₀	> 50 μM Compound: 1	Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 35544614]
U-251	GI₅₀	0.02 μM Compound: 49	Growth inhibition of human U-251 cells by sulforhodamine B assay Growth inhibition of human U-251 cells by sulforhodamine B assay	[PMID: 36375335]

In Vitro

Rutaecarpine has shown a variety of intriguing biological properties such as anti-thrombotic, anticancer, anti-inflammatory and analgesic, anti-obesity and thermoregulatory, vasorelaxing activity, as well as effects on the cardiovascular and endocrine systems^[2]. Rutaecarpine inhibits COX-2 and COX-1 dependent phases of PGD2 generation in BMMC in a concentration-dependent manner with an IC₅₀ of 0.28 μM and 8.7 μM, respectively. It inhibits COX-2-dependent conversion of exogenous arachidonic acid to PGE₂ in a dose-dependent manner by the COX-2-transfected HEK293 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rutaecarpine showed in vivo anti-inflammatory activity on rat l-carrageenan induced paw edema by intraperitoneal administration^[1]. Rutaecarpine significantly decreases the number of antibody-forming cells and causes weight decrease in spleen in a dose-dependent manner. In addition, rutaecarpine administered mice exhibit reduced splenic cellularity, decreased numbers of total T cells, CD4+ cells, CD8+ cells, and B cells in spleen. IL-2, interferon and IL-10 mRNA expressions are suppressed significantly by rutaecarpine treatment. The number of CD4+IL-2+ cells is reduced significantly following administration of mice with rutaecarpine^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

287.32

Formula

C₁₈H₁₃N₃O

CAS No.

84-26-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1N2C(C(NC3=C4C=CC=C3)=C4CC2)=NC5=C1C=CC=C5

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (174.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4804 mL	17.4022 mL	34.8044 mL
5 mM	0.6961 mL	3.4804 mL	6.9609 mL
10 mM	0.3480 mL	1.7402 mL	3.4804 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.09%

Select Batch:

Data Sheet (283 KB) SDS (254 KB)

COA (253 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Moon TC, et al. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res. 1999 Dec;48(12):621-5. [Content Brief]

[2]. Lee SH, et al. Progress in the studies on rutaecarpine. Molecules. 2008 Feb 6;13(2):272-300. [Content Brief]

[3]. Jeon TW, et al. Immunosuppressive effects of rutaecarpine in female BALB/c mice. Toxicol Lett. 2006 Jul 1;164(2):155-66. [Content Brief]

[4]. Xu M, et al. Rutaecarpine Attenuates Oxidative Stress-Induced Traumatic Brain Injury and Reduces Secondary Injury via the PGK1/KEAP1/NRF2 Signaling Pathway. Front Pharmacol. 2022 Apr 12;13:807125. [Content Brief]

Cell Assay ^[1]	Rutaecarpine is dissolved in DMSO and diluted with appropriate medium before use. COX-1 and COX-2 cDNA-transfected HEK293 cells are prepared. For measuring inhibitory activity on COX-1 and COX-2 by rutaecarpine, cells in 1 mL of culture medium are seeded into each well of 24-well. After culture for 4 days, the supernatants are removed and 250 mL of fresh medium is added to the cells with or without rutaecarpine. After preincubation for 5 h at 37°C, the cells are further incubated at 37°C for 30 min with 50 mM arachidonic acid. All reactions are stopped by centrifugation at 120 g at 4°C for 5 min. Concentrations of PGE2 in the supernatant are measured^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]^[3]	Rats: Rutaecarpine is dissolved in 0.1% carboxymethyl cellulose and diluted with appropriate medium before use. Male Splague-Dawley (SD) rats (180-220 g) are used in the study. Rutaecarpine administered intraperitoneally and, 1 h later, l-carrageenan solution is injected to right hind paw of rats. Paw volumes are measured using plethysmometer 5 h after l-carrageenan injection^[1]. Mice: For the antibody response to SRBCs, rutaecarpine is administered at a single dose of 10 mg/kg, 20 mg/kg, 40 mg/kg or 80 mg/kg in 10 mL of 1% povidone solution intravenously. Control animals are given 1% povidone solution at 10 mL/kg. Specific pathogen-free female BALB/c mice are used in the study^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Moon TC, et al. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm Res. 1999 Dec;48(12):621-5. [Content Brief] [2]. Lee SH, et al. Progress in the studies on rutaecarpine. Molecules. 2008 Feb 6;13(2):272-300. [Content Brief] [3]. Jeon TW, et al. Immunosuppressive effects of rutaecarpine in female BALB/c mice. Toxicol Lett. 2006 Jul 1;164(2):155-66. [Content Brief] [4]. Xu M, et al. Rutaecarpine Attenuates Oxidative Stress-Induced Traumatic Brain Injury and Reduces Secondary Injury via the PGK1/KEAP1/NRF2 Signaling Pathway. Front Pharmacol. 2022 Apr 12;13:807125. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.4804 mL	17.4022 mL	34.8044 mL	87.0110 mL
	5 mM	0.6961 mL	3.4804 mL	6.9609 mL	17.4022 mL
	10 mM	0.3480 mL	1.7402 mL	3.4804 mL	8.7011 mL
	15 mM	0.2320 mL	1.1601 mL	2.3203 mL	5.8007 mL
	20 mM	0.1740 mL	0.8701 mL	1.7402 mL	4.3505 mL
	25 mM	0.1392 mL	0.6961 mL	1.3922 mL	3.4804 mL
	30 mM	0.1160 mL	0.5801 mL	1.1601 mL	2.9004 mL
	40 mM	0.0870 mL	0.4351 mL	0.8701 mL	2.1753 mL
	50 mM	0.0696 mL	0.3480 mL	0.6961 mL	1.7402 mL
	60 mM	0.0580 mL	0.2900 mL	0.5801 mL	1.4502 mL
	80 mM	0.0435 mL	0.2175 mL	0.4351 mL	1.0876 mL
	100 mM	0.0348 mL	0.1740 mL	0.3480 mL	0.8701 mL

Rutaecarpine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rutaecarpine84-26-4RutecarpineCOXKeap1-Nrf2CyclooxygenaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Rutaecarpine (Synonyms: Rutecarpine)

Customer Review

Other Forms of Rutaecarpine:

Rutaecarpine Related Antibodies

6 Publications Citing Use of MCE Rutaecarpine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Rutaecarpine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Rutaecarpine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report